Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17128778 | 1.00 | GPBAR1 (0.72) | GPBAR1 | |
| SCHEMBL18799024 | 0.92 | GPBAR1 (0.84) | GPBAR1 | |
| SCHEMBL3781851 | 0.92 | GPBAR1 (0.84) | GPBAR1 | |
| SCHEMBL3787754 | 0.91 | GPBAR1 (0.71) | GPBAR1 | |
| SCHEMBL15362556 | 0.91 | GPBAR1 (0.71) | GPBAR1 | |
| SCHEMBL13814598 | 0.90 | GPBAR1 (0.70) | GPBAR1 | |
| SCHEMBL12447377 | 0.89 | GPBAR1 (0.69) | GPBAR1 | |
| SCHEMBL22251562 | 0.88 | NR1H4 (0.86) | GPBAR1 | |
| SCHEMBL3780915 | 0.88 | GPBAR1 (0.80) | GPBAR1 | |
| SCHEMBL15713590 | 0.88 | GPBAR1 (0.80) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2004-05-06 | — | — | US | claimed |
| EP-1292562-A1 | TRITERPENOID DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2003-03-19 | — | — | EP | claimed |
| US-6369109-B1 | Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2002-04-09 | — | — | US | claimed |
| WO-2001090046-A1 | TRITERPENOID DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2001-11-29 | — | — | WO | claimed |
| EP-1124842-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-08-22 | — | — | EP | claimed |
| WO-2000024762-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-05-04 | — | — | WO | claimed |
| US-7858606-B2 | Triterpenoid derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-28 | — | — | US | disclosed |
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2004-05-06 | — | — | US | disclosed |
| EP-1292562-A1 | TRITERPENOID DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2003-03-19 | — | — | EP | disclosed |
| US-6369109-B1 | Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2002-04-09 | — | — | US | disclosed |
| WO-2001090046-A1 | TRITERPENOID DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2001-11-29 | — | — | WO | disclosed |
| EP-1124842-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024762-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | MCL1, MKI67, CCNA1 | GPBAR1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.